UCB SA (VIE:UCB)

Market Cap	34.49B
Revenue (ttm)	5.45B
Net Income (ttm)	240.00M
Shares Out	n/a
EPS (ttm)	1.22
PE Ratio	143.71
Forward PE	n/a
Dividend	0.95 (0.53%)
Ex-Dividend Date	Apr 26, 2024

Volume	n/a
Average Volume	19
Open	181.40
Previous Close	182.50
Day's Range	180.95 - 181.90
52-Week Range	94.22 - 197.55
Beta	n/a
RSI	38.54
Earnings Date	Feb 27, 2025

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1925
• Employees: 9,083
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: UCB

Financial Performance

In 2023, UCB SA's revenue was 5.18 billion, a decrease of -4.87% compared to the previous year's 5.45 billion. Earnings were 343.00 million, a decrease of -17.94%.